Methdilazine

Summary

Methdilazine (CHEMBL1200959) is an approved small-molecule histamine antagonist (ATC R06AD04); indicated across 1 condition including allergic disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: R06AD04
• Indications: 1 condition
• Chemistry: 296.4 Da · C18H20N2S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200959
Name	Methdilazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	14677
ChEBI	CHEBI:6823
ATC	R06AD04
Molecular formula	C18H20N2S
Molecular weight	296.4
InChIKey	HTMIBDQKFHUPSX-UHFFFAOYSA-N

SMILES: CN1CCC(C1)CN2C3=CC=CC=C3SC4=CC=CC=C42

IUPAC name: 10-[(1-methylpyrrolidin-3-yl)methyl]phenothiazine

ChEBI definition: A phenothiazine substituted on nitrogen by a (1-methylpyrrolidin-3-yl)methyl group; a first-generation antihistamine with anticholinergic properties.

Pharmacological roles (ChEBI): histamine antagonist, cholinergic antagonist, antipruritic drug.

Also known as: Metdilazina, Methdilazine, Tacaryl, METHDILAZINE

Parent form; salt/anhydrous children: CHEMBL1200532

Patent coverage: 2,038 distinct patent families (5,944 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 5,890 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
allergic disease	4	MONDO:0005271	MONDO:0005271

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).